Ablynx launches European IPO
Gent, Belgium-based biopharmaceutical firm Ablynx, which focuses on the discovery and development of Nanobodies, has launched its initial public offering on the Eurolist of the Euronext Brussels.
The company hopes to raise nearly 99.2 million euros ($141.1 million) consisting of an offering to subscribe for up to 75.0 million euros in new shares with VVPR strips, which can be increased by a maximum of 15% to an amount of up to 86.25 million euros depending on the volume of demand. The price range of the offering has been set at a minimum of 6.5 euros and a maximum of 8.5 euros per share.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze